Since Hydroxychloroquine sulfate was recognized as a drug for treating COVID-19 by FDA on end Mar, the prices of its two main intermediates (4,7-Dichloroquinoline & Hydroxynovaldiamine) are sharply increasing again, but actually the current factories in China can't meet the domestic and foreign markets' huge demand on these 2 products, which brings new factories some chances to quickly set up this project of the above one or two intermediates.

Along with those 2 main intermediates' prices raising, their respective raw materials' prices are crazily increasing too, including 1) 4,7-Dichloroquinoline raw materials, such as Diethyl ethoxymethylenemalonate (EMME), 3-Chloroaniline, or even remote products Triethyl Orthoformate (TEOF), Diethyl malonate, Meta Nitro Chorobenzene (MNCB), etc.; and 2) Hydroxynovaldiamine raw materials, such as 5-Chloro-2-pentanone, or even remote products 2-Acetylbutyrolactone (ABL), 2-Methylfuran, Gamma-Butyrolactone (GBL), etc.

However, we have to pay attention to 2 factors which possibly influence the prices trend of those 2 intermediates and their raw materials, namely: the actual effectiveness of Hydroxychloroquine sulfate to treat COVID-19 and the global epidemic control of COVID-19.

                                                                                                                       Edited by Relybo